Skip to content

Study · Non-randomized trial · n = 7 · 1984

2 results

Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.

Larbig W, Gerber WD, Kluck M, Schoenenberger GA

European neurology1 Jan 1984Cited by 7 (Europe PMC)

PMID6548970 (opens in a new tab)DOI10.1159/000115716 (opens in a new tab)PepBankPUB-06548970
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In 7 patients with chronic pain episodes, DSIP significantly lowered pain levels in 6 of 7 patients versus baseline.

    In plain wordsIn 7 patients with chronic pain, DSIP lowered pain in 6 of 7 compared with before treatment, without a placebo group.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreasePain levels
    Study

    n = 7

    Comparator
    Baseline (anamnestic) values
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intravenous · 5 consecutive days followed by 5 injections every 48-72 hAs given in this study (human).

    Measurements

    Patients with significantly lower pain
    6 of 7
    DSIP

    Source sentences

    Summary
    DSIP lowered significantly the pain levels of 6 out of 7 patients after intravenous administration on 5 consecutive days followed by 5 injections every 48-72 h.
    2 context sentences
    Summary · context
    We investigated the therapeutic effect in 7 patients with migraine episodes and vasomotor headaches, chronic tinnitus and psychogenic pain attacks.
    Summary · context
    The anamnestic (baseline) values were statistically compared with the katamnestic control period.
  2. 02HumanNon-randomized trialEfficacy outcome

    In 7 patients with chronic pain episodes, DSIP was accompanied by a significant reduction of concomitant depressive states.

    In plain wordsIn 7 patients with chronic pain, depressive states also fell significantly compared with before treatment, without a placebo group.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    DecreaseDepressive states
    Study

    n = 7

    Comparator
    Baseline (anamnestic) values
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intravenous · 5 consecutive days followed by 5 injections every 48-72 hAs given in this study (human).

    Source sentences

    Summary
    Remarkably, a simultaneous significant reduction of the concomitantly occurring depressive states was observed.
    2 context sentences
    Summary · context
    We investigated the therapeutic effect in 7 patients with migraine episodes and vasomotor headaches, chronic tinnitus and psychogenic pain attacks.
    Summary · context
    The anamnestic (baseline) values were statistically compared with the katamnestic control period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.